Program Schedule

422
Antimicrobial Susceptibility Profiles of Key Blood and Respiratory Bacterial Isolates from Africa and the Middle East

Session: Poster Abstract Session: Surveillance of Antimicrobial Resistance
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC

 

Background: Enterobacteriaceae , P. aeruginosa and A. baumannii can cause serious infections, particularly among hospitalized patients.   Each of these organism groups have a propensity to exhibit resistance to many of the drugs used to manage the infections that they cause. Therefore, careful monitoring of the resistance patterns they exhibit is warranted.  In this study Tigecycline Evaluation Surveillance Trial (TEST) program data were used to evaluate the in vitro activity of several key drugs against blood and respiratory isolates from Africa and the Middle East (AFME).

Methods: A total of 1,591 isolates collected from AFME (Egypt, Morocco, Mauritius, Namibia, South Africa, Tunisia, Israel, Jordan, Lebanon, Oman, Saudi Arabia; 2011-2013) were identified and tested locally by broth microdilution according to CLSI guidelines.  All data were collected centrally at IHMA for analysis. 

Results : The activities of the various drugs according to specimen source and organism group are provided in the Table below.

Enterobacteriaeae(2475)

P. aeruginosa (528)

A. baumannii (398)

 

Blood (596)

Resp. (386)

Blood (82)

Resp. (162)

Blood (92)

Resp.(139)

Drug

%S

MIC90

%S

MIC90

%S

MIC90

%S

MIC90

%S

MIC90

%S

MIC90

Amikacin

95.6

8

95.1

8

95.1

16

86

32

27.2

> 64

30.9

> 64

Ceftazidime

49.8

> 16

58.0

> 16

64.6

32

71.0

> 16

13.0

32

6.5

> 32

Levofloxacin

73.0

> 8

79

> 8

79.3

> 8

66.7

> 8

18.5

> 8

10.8

> 8

Meropenem

95

0.5

94.8

0.5

81.7

8

69.1

16

14.1

> 16

10.1

> 16

Pip-tazo

80.0

128

81.4

128

73.2

> 128

75.3

64

8.7

> 128

6.5

> 128

Tigecycline

96.8

2

95.3

2

naa

na

na

na

na

na

na

na

ana: not applicable

Conclusion:  Based on percent susceptibility and MIC90's amikacin, meropenem, and tigecycline were the most active agents against Enterobacteriaceae, regardless of specimen source.   For P. aeruginosa  amikacin was the most active with all others having percent susceptibilities near or below 80%.  None of the agents had effective activity against A. baummannii..  These variations in antimicrobial susceptibilities underscore the need for continued monitoring of resistance trends among these clinical important organism groups encountered in AFME

Martha Renteria, MD1, Dan Sahm, PhD1 and Heidi Leister-Tebbe, BS2, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer Inc., Collegeville, PA

Disclosures:

M. Renteria, Pfizer: Independent Contractor, Consulting fee

D. Sahm, Pfizer: Independent Contractor, Consulting fee

H. Leister-Tebbe, Pfizer: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek